Skip to main content
. 2020 Jan 31;2(1):e190024. doi: 10.1148/rycan.2020190024

Figure 6b:

Figure 6b:

Persistent tumoral enhancement (diffuse central, nodular central, or peripheral) after transarterial radioembolization (TARE) in a 67-year-old man. (a) Axial arterial phase pretreatment MR image demonstrates a 7.2-cm LI-RADS 5/OPTN 5× hepatocellular carcinoma (arrow) with arterial phase hyperenhancement (APHE), “washout” and “capsule” (b). (c) Axial arterial phase MR image 3 months after TARE shows the tumor is unchanged in size with persistent diffuse central APHE, “washout” and “capsule” (d) (mRECIST SD, LR-TR equivocal vs nonviable). (e) Six months after TARE therapy, the tumor measures 3.3 cm with decreasing central enhancement and persistent peripheral nodular APHE, seen at arterial phase MRI, which persists at portal venous (PV) phase of imaging (f) (mRECIST PR, LR-TR nonviable). (g) Twelve months after TARE, the tumor continues to decrease in size, measuring 3.0 cm, with no residual tumoral enhancement, confirmed with subtraction imaging (mRECIST CR, LR-TR nonviable). CR = complete response, LR = LI-RADS, mRECIST = modified Response Evaluation Criteria for Solid Tumors, OPTN = Organ Procurement and Transplantation Network, SD = stable disease, TR = treatment response.